查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018602

CRISPR和Cas基因市場：按Cas類型、遞送方法、技術、應用和最終用戶分類－2026-2032年全球市場預測

CRISPR & Cas Genes Market by Cas Type, Delivery Method, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，CRISPR 和 Cas 基因市場價值將達到 67.3 億美元，到 2026 年將成長到 90 億美元，到 2032 年將達到 523.6 億美元，年複合成長率為 34.03%。

主要市場統計數據
基準年 2025 67.3億美元
預計年份：2026年 90億美元
預測年份 2032 523.6億美元
複合年成長率 (%) 34.03%

概述 CRISPR 和 Cas 基因的演變，以及在研究、轉化和商業化功能方面進行策略協調的必要性。

CRISPR及其相關的Cas基因系統已從實驗室工具迅速發展成為支撐現代基因編輯、診斷和治療方法設計的基礎平台。本文概述了CRISPR-Cas的技術發展歷程，其從基礎研究到應用流程的轉變，以及遞送技術創新、多重編輯策略和診斷技術整合等融合趨勢如何重塑轉化研究的時間線。本文將重點在於闡述生物技術、生物製藥、合約研究組織（CRO）和學術研究機構的領導者為何必須調整其研究策略以適應這些新的平台功能。

分子發現、遞送工程、診斷技術的整合以及日益成熟的法規環境如何從整體上重塑發展路徑和策略重點。

CRISPR和Cas系統正經歷著一場變革性的轉變，這得益於分子發現、遞送工程以及與診斷和計算生物學跨學科融合的同步發展。新型Cas效應蛋白和修飾變異的發現正在拓展分子工具箱，使以往無法觸及的新型標靶類型和編輯技術成為可能。同時，從非病毒奈米顆粒到改良的病毒載體和電穿孔方案，遞送技術的創新使得對編輯活性進行時空控制成為可能，從而降低了脫靶風險並提高了治療指數。

了解關稅壓力對供應鏈和採購的影響如何促使供應鏈多樣化、考慮本地製造以及 CRISPR 專案中的韌性策略。

關稅的引入會改變供應鏈、採購成本以及實驗室和生產設施取得設備和試劑的速度。在 CRISPR 和 Cas 系統中，關鍵投入包括專用酵素和試劑、用於細胞操作和定序的精密儀器，以及用於遞送方法（例如脂質奈米顆粒化學）的生產組件和病毒載體生產的耗材。如果關稅帶來的成本壓力影響了這些投入的經濟可行性，各機構將優先考慮供應的連續性，選擇替代供應商，或將部分供應鏈本地化，以維持專案進度。

將應用程式、最終用戶、CAS 類型、交付方式和技術路徑連結起來的多維細分分析，可指導投資和營運決策。

精細化的細分觀點為轉換和商業化路徑的優先順序提供了切實可行的指南。基於應用領域，研究團隊和商業負責人需要區分在農業生物技術、動物模型開發、診斷、基因編輯和基因治療等領域的投資。值得注意的是，診斷可細分為疾病檢測和基因篩檢，而基因編輯則可分為研究應用和治療應用。這種多層次的應用細分有助於明確監管複雜性、報銷途徑和療效顯現時間方面存在顯著差異的領域。

美洲、歐洲、中東和非洲以及亞太地區的區域發展狀況、監管差異和投資趨勢影響實施和營運策略。

區域趨勢影響CRISPR和Cas基因技術的研發、資金籌措和部署，了解這些地理差異對於有效分配商業性和營運資源至關重要。美洲擁有強大的公共和私人投資生態系統，通常支持高風險的轉化項目。這裡創業投資活動活躍，領先的臨床開發中心正在加速I期人體試驗。雖然該地區在平台型Start-Ups和連接學術創新與商業性規模的合作中往往發揮著主導作用，但也面臨著嚴格的監管審查和支付方趨勢的影響，這些因素都會影響臨床開發策略。

平台廣度、交付能力、臨床執行能力、生產規模和策略夥伴關係關係如何決定競爭優勢和合作機會。

CRISPR和Cas基因生態系統中的企業策略正趨向於一系列差異化因素：平台廣度、遞送技術、臨床執行能力、生產規模和策略夥伴關係。平台廣度對於旨在開拓多個治療領域和診斷應用的公司至關重要，因為它能夠實現資產多元化和跨專案知識共用。遞送技術是關鍵的競爭優勢。能夠可靠地提供安全性高的編輯機制的企業，能夠獲得更高的策略性溢價，並更有能力與大規模臨床開發公司建立合作關係。

有針對性的營運和夥伴關係措施，以降低研發管線風險，擴大生產模組化，並加速 CRISPR-Cas 基因舉措符合監管規定的實用化。

產業領導企業應採取一系列切實可行的優先事項，將洞察轉化為可衡量的進展。首先，優先考慮供應商和交付冗餘，透過選擇備選試劑和儀器供應商並檢驗多種交付方式，降低專案進度風險。其次，投資於可在體外和體內專案中重複使用的模組化生產和品質體系，在滿足不斷變化的監管要求的同時，最大限度地提高資本效率。第三，透過將早期監管合作與完善的安全性和監測計畫結合，簡化轉換路徑並降低後期試驗的失敗率。

採用混合方法研究方法，結合一手訪談、文獻整合、監管分析和情境測試，以檢驗策略結論和假設。

本分析的調查方法透過嚴格整合一手和二手訊息，確保了其實用可靠性。一手資訊包括對生物技術公司、合約研究組織 (CRO)、藥物研發團隊和學術研究人員的技術負責人進行的結構化訪談，並輔以生產和監管專家的直接意見。二手資訊整合了同儕審查文獻、公開的監管指南、專利分析和臨床試驗註冊數據，以全面檢驗計畫發展軌跡和技術應用模式。

將平台成熟度、供應彈性、交付創新和夥伴關係關係的需求整合起來，以將 CRISPR 科學轉化為永續的臨床和商業性成果。

總之，CRISPR和Cas基因系統正從分散的實驗室技術轉型為涵蓋診斷、治療和農業的整合平台。關鍵轉折點包括遞送技術的成熟、具有互補功能的多種Cas效應蛋白的出現，以及強調可重複性和安全性的不斷演變的法規環境。這些趨勢既帶來了機遇，也帶來了挑戰。投資於多元化發行策略、建立穩健供應鏈和建立有針對性的夥伴關係關係的機構，將更有利於獲取轉化價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按Cas類型分類的CRISPR和Cas基因市場

  • Cas12
  • Cas13
  • Cas14
  • Cas9

第9章：CRISPR和Cas基因市場：按遞送方式分類

  • 電穿孔
  • 脂質體轉染
  • 顯微注射
  • 奈米顆粒遞送
    • 脂質奈米顆粒
    • 聚合物奈米粒子
  • 病毒載體
    • 腺結合病毒
    • 腺病毒
    • 慢病毒

第10章：CRISPR和Cas基因市場：依技術分類

  • Ex Vivo
    • 細胞株改造
    • 原始細胞的改造
  • In vivo
    • 臨床試驗
    • 臨床前模型

第11章：CRISPR和Cas基因市場：按應用領域分類

  • 農業生物技術
  • 動物模型開發
  • 診斷
    • 疾病檢測
    • 基因篩檢
  • 基因編輯
    • 出於研究目的
    • 治療用途
  • 基因治療

第12章：CRISPR和Cas基因市場：依最終用戶分類

  • 生技公司
    • 現有公司
    • Start-Ups
  • 合約研究機構
    • 臨床服務
    • 臨床前服務
  • 製藥公司
    • 生物製藥公司
    • 大型製藥企業
  • 研究機構

第13章：CRISPR和Cas基因市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：CRISPR和Cas基因市場：按組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：CRISPR和Cas基因市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國 CRISPR 和 Cas 基因市場

第17章：中國CRISPR和Cas基因市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Addgene
  • AstraZeneca PLC
  • Bayer AG
  • Beam Therapeutics Inc.
  • Beckman Coulter, Inc.
  • Calyxt, Inc.
  • Caribou Biosciences, Inc.
  • Cellectis plant sciences, Inc.
  • Corteva, Inc.
  • CRISPR Therapeutics AG
  • Danaher Corporation
  • Editas Medicine, Inc.
  • GenScript Biotech Corporation
  • Hera Biolabs
  • Inscripta, Inc.
  • Integrated DNA Technologies, Inc.
  • Intellia Therapeutics, Inc.
  • Lonza Group Ltd.
  • Mammoth Biosciences, Inc.
  • Merck KGaA
  • OriGene Technologies, Inc.
  • PerkinElmer, Inc.
  • Sangamo Therapeutics, Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-5642D503D83C

The CRISPR & Cas Genes Market was valued at USD 6.73 billion in 2025 and is projected to grow to USD 9.00 billion in 2026, with a CAGR of 34.03%, reaching USD 52.36 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.73 billion
Estimated Year [2026] USD 9.00 billion
Forecast Year [2032] USD 52.36 billion
CAGR (%) 34.03%

A concise framing of CRISPR and Cas gene evolution and the imperative for strategic alignment across research, translational, and commercialization functions

CRISPR and its associated Cas gene systems have rapidly evolved from a laboratory tool into a foundational platform that underpins modern gene editing, diagnostics, and therapeutic design. This introduction synthesizes the technical lineage of CRISPR-Cas, its transition from basic research into applied pipelines, and the converging trends-such as delivery innovation, multiplex editing strategies, and diagnostic integration-that are reshaping translational timelines. In doing so, it frames why organizational leaders across biotechnology, biopharma, contract research organizations, and academic centers must align research strategy with emergent platform capabilities.

As the field matures, emphasis is shifting from proof-of-concept edits to reproducible, scalable, and regulatory-compliant workflows. Novel Cas variants, improved delivery modalities, and paired diagnostic-readouts have collectively lowered barriers to clinical translation while simultaneously amplifying the technical and commercial complexity teams must navigate. This introduction therefore sets the scene for deeper sections that address landscape shifts, tariff-driven supply considerations, segmentation intelligence, and region-specific dynamics, all of which inform operational choices for science, regulatory, and commercial leaders.

How molecular discovery, delivery engineering, diagnostic convergence, and regulatory maturation are collectively reshaping development pathways and strategic priorities

The landscape for CRISPR and Cas systems is undergoing transformative shifts driven by parallel advances in molecular discovery, delivery engineering, and cross-disciplinary integration with diagnostics and computational biology. Discovery of alternative Cas effectors and engineered variants is expanding the molecular toolbox, enabling new target classes and editing modalities that were previously inaccessible. Concomitantly, delivery innovations-ranging from nonviral nanoparticles to refined viral vectors and electroporation protocols-are enabling spatial and temporal control over editing activity, which in turn reduces off-target risk and enhances therapeutic index.

Translationally, diagnostics are converging with editing platforms to create closed-loop workflows where detection, stratification, and treatment are more tightly coupled. This shift is accelerating use cases in precision infectious disease diagnostics, point-of-care genetic screening, and in situ therapeutic monitoring. The regulatory environment is also maturing, with agencies publishing guidance on human somatic genome editing and diagnostics that emphasize safety, traceability, and reproducibility. As a result, organizations are moving from single-asset projects to platform-oriented strategies that center on scalable manufacturing, standardized quality systems, and partnerships across delivery, analytics, and clinical operations. Together, these dynamics are changing how programs are designed, funded, and executed across the ecosystem.

Understanding how tariff-driven supply chain and procurement pressures compel supply diversification, local manufacturing considerations, and resilience strategies for CRISPR programs

The introduction of tariffs can alter supply chains, procurement costs, and the cadence of equipment and reagent availability for laboratories and manufacturing facilities. In the context of CRISPR and Cas systems, key inputs include specialized enzymes and reagents, precision instrumentation for cell manipulation and sequencing, and components for manufacturing delivery modalities such as lipid nanoparticle chemistries and viral vector production consumables. When tariff-driven cost pressure changes the economics of these inputs, organizations respond by prioritizing supply continuity, qualifying alternative suppliers, or localizing portions of their supply base to preserve program timelines.

Operationally, leaders are incentivized to reassess inventory strategies, invest in redundant or regionally distributed suppliers, and accelerate vendor qualification protocols. For translational programs, any delay or variance in critical supplies can cascade into longer preclinical timelines or deferred clinical activities, creating opportunity costs for pipelines. Trade policy friction also influences strategic sourcing decisions for high-value capital equipment such as cell processing and high-throughput sequencing platforms, prompting organizations to renegotiate service-level agreements or explore refurbished and domestically produced alternatives. In sum, tariff impacts manifest not only as direct cost pressures but as strategic drivers of supply resilience, local manufacturing consideration, and supplier diversification across R&D and manufacturing operations.

Multidimensional segmentation intelligence linking application, end user, Cas type, delivery modality, and technology pathways to guide investment and operational choices

A granular segmentation view provides practical levers for prioritization across translational and commercial pathways. Based on Application, research teams and commercial strategists must differentiate investments across Agricultural Biotechnology, Animal Model Development, Diagnostics, Gene Editing, and Gene Therapy, recognizing that Diagnostics is further divided into Disease Detection and Genetic Screening while Gene Editing splits into Research Applications and Therapeutic Applications. This layered application segmentation clarifies where regulatory complexity, reimbursement pathways, and time-to-impact differ markedly.

Based on End User, the ecosystem dynamics change depending on the buyer and operator: Biotechnology Companies, Contract Research Organizations, Pharmaceutical Companies, and Research Institutes each bring different procurement rhythms and risk tolerances. Within this, Biotechnology Companies can be viewed through the lens of Established Firms versus Startups; Contract Research Organizations separate into Clinical Services and Preclinical Services; and Pharmaceutical Companies include both Biopharma Firms and Large Pharma. These distinctions matter for partner selection, contracting models, and commercialization timelines.

Based on Cas Type, applications track to molecular capability: Cas12, Cas13, Cas14, and Cas9 each have distinct biochemical properties and target class compatibilities, which influence assay design, therapeutic targeting, and IP considerations. Based on Delivery Method, practical trade-offs exist among Electroporation, Liposome Transfection, Microinjection, Nanoparticle Delivery, and Viral Vector, with Nanoparticle Delivery subdividing into Lipid Nanoparticles and Polymer Nanoparticles and Viral Vector further subdividing into Adeno Associated Virus, Adenovirus, and Lentivirus. Each delivery option requires different manufacturing capabilities, regulatory dossiers, and safety-monitoring frameworks.

Finally, Based on Technology, programs diverge along Ex Vivo and In Vivo pathways. Ex Vivo work is refined into Cell Line Engineering and Primary Cell Modification, which often emphasizes process control and closed-system manufacturing, while In Vivo approaches encompass Clinical Trials and Preclinical Models and prioritize biodistribution, immunogenicity, and delivery optimization. Together, these segmentation layers create a multidimensional view that helps leaders prioritize where to allocate capital, how to structure partnerships, and which operational capabilities to develop internally.

Regional development, regulatory variation, and investment dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific shaping adoption and operational strategy

Regional dynamics shape how CRISPR and Cas gene technologies are developed, funded, and adopted, and understanding geographic nuances helps allocate commercial and operational resources effectively. In the Americas, public and private investment ecosystems are robust and often support high-risk translational projects, with strong venture capital activity and major clinical development centers that accelerate first-in-human studies. This region tends to lead in platform startups and partnering transactions that bridge academic innovation and commercial scaling, while also facing concentrated regulatory scrutiny and payer dynamics that influence clinical development strategies.

Europe, Middle East & Africa present a heterogeneous regulatory and funding landscape where collaborative research networks, strong academic hubs, and strategic national initiatives coexist with varied reimbursement systems and approval timelines. Regional centers of excellence emphasize translational rigor and early patient engagement, and cross-border collaborations are common to access patient cohorts and diverse expertise. Concurrently, nations within the region prioritize different technology pathways based on local public health needs and industrial policy.

Asia-Pacific exhibits rapid adoption driven by significant public R&D investment, expanding domestic biopharma capability, and a growing manufacturing base for biologics and delivery systems. Several markets are actively building clinical trial capacity and local regulatory clarity to attract global development programs. As a result, Asia-Pacific is increasingly important for scaling manufacturing, accessing diverse patient populations, and sourcing specialized reagents and components, making it an essential region for global operational planning.

How platform breadth, delivery capability, clinical execution, manufacturing scale, and strategic partnerships define competitive advantage and partnership opportunities

Company strategies in the CRISPR and Cas gene ecosystem are converging around a set of differentiators: platform breadth, delivery expertise, clinical execution capability, manufacturing scale, and strategic partnerships. Platform breadth is valuable for firms that aim to address multiple therapeutic areas or diagnostic applications, because it enables asset-level diversification and cross-program learning. Delivery expertise has become a critical competitive moat; organizations that can reliably deliver editing machinery with favorable safety profiles command a higher strategic premium and greater ability to partner with large clinical developers.

Clinical execution and regulatory navigation distinguish companies that successfully transition from discovery-stage programs to late-stage development. Firms investing early in manufacturing and quality systems shorten the timeline from clinical proof-of-concept to commercial readiness. Strategic partnerships, whether they are co-development agreements, technology licensing, or manufacturing collaborations, are central to scale-up strategies and risk-sharing. Across the ecosystem, successful companies combine deep technical expertise with operational dexterity, aligning R&D pipelines to pragmatic commercialization routes and forming partnerships that address gaps in delivery, analytics, and regulatory affairs.

Targeted operational and partnership actions to de-risk pipelines, scale manufacturing modularity, and accelerate regulated translation of CRISPR and Cas gene initiatives

Industry leaders should adopt a set of actionable priorities that translate insight into measurable progress. First, prioritize supplier and delivery redundancy by qualifying alternative reagent and equipment suppliers, and by validating multiple delivery approaches to de-risk program timelines. Second, invest in modular manufacturing and quality systems that can be repurposed across ex vivo and in vivo programs to maximize capital efficiency while meeting evolving regulatory expectations. Third, align early regulatory engagement with robust safety and monitoring plans to streamline translational pathways and reduce later-stage attrition.

In parallel, pursue strategic collaborations that complement internal capabilities: partner with specialized CDMOs and delivery technology providers to accelerate manufacturing scale, and form data partnerships to enhance diagnostic and stratification strategies. Build internal capabilities in analytical characterization and bioinformatics to optimize editing specificity and to support regulatory dossiers. Finally, develop market-access playbooks that integrate diagnostic companion strategies, payer engagement, and clear value narratives to support commercialization decisions. These actions create a defensible, pragmatic path from innovation to sustained clinical and commercial impact.

A mixed-methods research approach combining primary interviews, literature synthesis, regulatory analysis, and scenario testing to validate strategic conclusions and assumptions

The research methodology underpinning this analysis blends primary and secondary intelligence with rigorous synthesis to ensure actionable reliability. Primary inputs include structured interviews with technical leaders across biotech, contract research organizations, pharmaceutical development teams, and academic investigators, supplemented by direct input from manufacturing and regulatory professionals. Secondary inputs incorporate peer-reviewed literature, publicly available regulatory guidance, patent analysis, and clinical trial registry data to triangulate program trajectories and technology adoption patterns.

Analytical approaches applied include technology readiness assessments, supply chain stress-testing, and scenario planning that incorporates policy and trade variables. Where appropriate, cross-validation was used to reconcile divergent perspectives, ensuring conclusions reflect consensus where it exists and clearly flag areas of uncertainty. This mixed-method approach provides executives with a robust base of evidence to inform strategy, while also highlighting critical assumptions and sensitivity points that merit ongoing monitoring.

Synthesis of platform maturation, supply resilience, delivery innovation, and partnership imperatives to convert CRISPR science into durable clinical and commercial outcomes

In conclusion, CRISPR and Cas gene systems are transitioning from compartmentalized laboratory methods to integrated platforms that span diagnostics, therapeutics, and agriculture. Key inflection points include maturation of delivery technologies, the emergence of multiple Cas effectors with complementary capabilities, and an evolving regulatory environment that emphasizes reproducibility and safety. These dynamics create both opportunity and complexity: organizations that invest in diversified delivery strategies, resilient supply chains, and targeted partnerships will be best positioned to capture translational value.

Looking ahead, executives should balance near-term operational resilience with longer-term platform investments. Prioritizing modular manufacturing, regulatory foresight, and cross-sector partnerships will enable organizations to convert technical innovation into clinical and commercial outcomes. Sustained progress will depend on disciplined execution, transparent data practices, and continued investment in delivery and analytics capabilities that together reduce technical risk and improve patient and market impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. CRISPR & Cas Genes Market, by Cas Type

  • 8.1. Cas12
  • 8.2. Cas13
  • 8.3. Cas14
  • 8.4. Cas9

9. CRISPR & Cas Genes Market, by Delivery Method

  • 9.1. Electroporation
  • 9.2. Liposome Transfection
  • 9.3. Microinjection
  • 9.4. Nanoparticle Delivery
    • 9.4.1. Lipid Nanoparticles
    • 9.4.2. Polymer Nanoparticles
  • 9.5. Viral Vector
    • 9.5.1. Adeno Associated Virus
    • 9.5.2. Adenovirus
    • 9.5.3. Lentivirus

10. CRISPR & Cas Genes Market, by Technology

  • 10.1. Ex Vivo
    • 10.1.1. Cell Line Engineering
    • 10.1.2. Primary Cell Modification
  • 10.2. In Vivo
    • 10.2.1. Clinical Trials
    • 10.2.2. Preclinical Models

11. CRISPR & Cas Genes Market, by Application

  • 11.1. Agricultural Biotechnology
  • 11.2. Animal Model Development
  • 11.3. Diagnostics
    • 11.3.1. Disease Detection
    • 11.3.2. Genetic Screening
  • 11.4. Gene Editing
    • 11.4.1. Research Applications
    • 11.4.2. Therapeutic Applications
  • 11.5. Gene Therapy

12. CRISPR & Cas Genes Market, by End User

  • 12.1. Biotechnology Companies
    • 12.1.1. Established Firms
    • 12.1.2. Startups
  • 12.2. Contract Research Organizations
    • 12.2.1. Clinical Services
    • 12.2.2. Preclinical Services
  • 12.3. Pharmaceutical Companies
    • 12.3.1. Biopharma Firms
    • 12.3.2. Large Pharma
  • 12.4. Research Institutes

13. CRISPR & Cas Genes Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. CRISPR & Cas Genes Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. CRISPR & Cas Genes Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States CRISPR & Cas Genes Market

17. China CRISPR & Cas Genes Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Addgene
  • 18.6. AstraZeneca PLC
  • 18.7. Bayer AG
  • 18.8. Beam Therapeutics Inc.
  • 18.9. Beckman Coulter, Inc.
  • 18.10. Calyxt, Inc.
  • 18.11. Caribou Biosciences, Inc.
  • 18.12. Cellectis plant sciences, Inc.
  • 18.13. Corteva, Inc.
  • 18.14. CRISPR Therapeutics AG
  • 18.15. Danaher Corporation
  • 18.16. Editas Medicine, Inc.
  • 18.17. GenScript Biotech Corporation
  • 18.18. Hera Biolabs
  • 18.19. Inscripta, Inc.
  • 18.20. Integrated DNA Technologies, Inc.
  • 18.21. Intellia Therapeutics, Inc.
  • 18.22. Lonza Group Ltd.
  • 18.23. Mammoth Biosciences, Inc.
  • 18.24. Merck KGaA
  • 18.25. OriGene Technologies, Inc.
  • 18.26. PerkinElmer, Inc.
  • 18.27. Sangamo Therapeutics, Inc.
  • 18.28. Takara Bio Inc.
  • 18.29. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CRISPR & CAS GENES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CRISPR & CAS GENES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CRISPR & CAS GENES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CRISPR & CAS GENES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CRISPR & CAS GENES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CRISPR & CAS GENES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS12, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS12, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS12, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS13, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS13, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS13, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS14, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS14, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS14, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS9, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS9, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS9, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIPOSOME TRANSFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIPOSOME TRANSFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIPOSOME TRANSFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY MICROINJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY MICROINJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY MICROINJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY POLYMER NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY POLYMER NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY POLYMER NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LENTIVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LENTIVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LENTIVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CELL LINE ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CELL LINE ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CELL LINE ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRIMARY CELL MODIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRIMARY CELL MODIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRIMARY CELL MODIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CLINICAL TRIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CLINICAL TRIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRECLINICAL MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRECLINICAL MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRECLINICAL MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY AGRICULTURAL BIOTECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY AGRICULTURAL BIOTECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ANIMAL MODEL DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ANIMAL MODEL DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ANIMAL MODEL DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DISEASE DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DISEASE DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DISEASE DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENETIC SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENETIC SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENETIC SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY RESEARCH APPLICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY RESEARCH APPLICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ESTABLISHED FIRMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ESTABLISHED FIRMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ESTABLISHED FIRMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY STARTUPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY STARTUPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY STARTUPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CLINICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CLINICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CLINICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRECLINICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRECLINICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRECLINICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOPHARMA FIRMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOPHARMA FIRMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOPHARMA FIRMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LARGE PHARMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA CRISPR & CAS GENES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 254. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 270. GCC CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. GCC CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. GCC CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 273. GCC CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 274. GCC CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 275. GCC CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 276. GCC CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 277. GCC CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 278. GCC CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 279. GCC CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 280. GCC CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 281. GCC CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. GCC CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 283. GCC CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 284. GCC CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. BRICS CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 303. BRICS CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 304. BRICS CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 305. BRICS CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 306. BRICS CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 307. BRICS CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 308. BRICS CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 309. BRICS CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 310. BRICS CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 311. BRICS CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 312. BRICS CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 313. BRICS CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 314. BRICS CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 315. G7 CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 316. G7 CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. G7 CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 318. G7 CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 319. G7 CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 320. G7 CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 321. G7 CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 322. G7 CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 323. G7 CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 324. G7 CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 325. G7 CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 326. G7 CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 327. G7 CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 328. G7 CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 329. G7 CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 330. NATO CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)

TABLE 331